European Commission approves Roche MabThera for treatment of adult patients with moderate to severe normal herpes

PV is a rare, serious and potentially life-threatening autoimmune disease characterized by progressive pain blistering in the skin and mucous membranes, accounting for about 80% of herpes casesrecently, SwissPharmaceuticals(http://giant Roche announced that the European Commission (EC) has approved MabThera (meratximab, rituximab, rituxixim) for the treatment of patients with moderate to severe normal type of osteopher (PV) adult patientsMabThera/Rituxan is a therapeutic monoclonal antibody that targets CD20 antigens that bind to the surface of normal and malignant B cells, then mobilizes the body's natural defenses to attack and kill labeled B cellsIn the U.S.,FDA(http://approved the treatment of Miroita (U.Smarket name: Rituxan) in June 2018To date, melo-chinese have been approved for the treatment of four autoimmune diseases in the United States and the European Union, including: rheumatoid arthritis (RA), granuloma polyvascularitis (GPA), microscopy polyvascularitis (MPA), and PVThis approval is based on data from clinical research Ritux 3The study was a forward-looking, multicenter, random, parallel, open label study in 90 patients with moderate to severe PV diagnosisinstudy, patients were randomly divided into two programme groups: (1) CS standard dose protocol group; The main endpoint of the study was to achieve complete remission in the 24th month of treatment (defined as complete epitherapy without using steroids for 2 months or more) and without new and/or formed lesionsresults show that Rituxan significantly increased the rate of PV remission while successfully reducing and/or discontinuing CS therapy The specific data were: 89.5% of patients in the Rituxan-CS scheme group reached the end point, and only 27.8% of the CS programme group 　　Currently, Roche is conducting another Phase III study of PEMPHIX (NCT02383589) to assess the efficacy and safety of the Rituxan combined dose of cS in relation to immunosuppressive drug (http:// Cellcept (McCophenolic acid)